Unfavorable prognosis is often related to mutational activation of PI3K/Akt signaling [19,20,21], whose inhibition has in fact been shown to increase therapy sensitivity in a tumor subgroup, as revealed using patient-derived xenograft models [48]. The gene discussed is AKT1; the disease is neoplasm.